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Abstract:  
Background/Aims: Youth with type 2 diabetes (T2D) have poor compliance with medical care. 
This study aimed to determine which demographic and clinical factors differ between youth with 
T2D who receive care in a pediatric diabetes center vs. youth lost to follow-up for >18 months.   
Methods: Data were analyzed from 496 subjects in the Pediatric Diabetes Consortium registry. 
Enrollment variables were selected a priori and analyzed with univariable and multivariable 
logistic regression models.  
Results: After a median of 1.3 years from enrollment 55% of patients were lost to follow-up. The 
final model included age, race/ethnicity, parent education and estimated distance to study site. 
The odds ratio (99% confidence interval) of lost to follow-up was 2.87 (1.34, 6.16) for those 15 - 
<18 years old vs. 10 - <13 years old, and was 6.57 (2.67, 16.15) for ≥ 18 years old vs. those 10 - 
<13 years old. Among patients living more than 50 miles from the clinic, the odds ratio of lost to 
follow-up was 3.11 (1.14, 8.49) vs. those living within 5 miles of the site.   
Conclusion: Older adolescents with T2D are more likely to be lost to follow-up, but other 
socioeconomic factors were not significant predictors of clinic follow-up.  
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Introduction 
Type 2 diabetes (T2D) is a growing pediatric health concern, accounting for 22% of new 
diabetes cases among youth in the United States [1]. It is estimated that the number of youth with 
T2D will increase 4-fold by 2050 [2]. In addition, youth diagnosed with T2D have increased 
morbidity and mortality compared with youth diagnosed with type 1 diabetes (T1D) [3] or those 
diagnosed with T2D at greater than 30 years of age [4]. Youth diagnosed with T2D are at 
particularly high risk of early nephropathy. Fifteen years after diagnosis, 26% of youth with T2D 
have experienced at least one major complication (dialysis, blindness or amputations) [5]. The 
rate of major complications increases to 47.9% twenty years after diagnosis [5]. In T2D, 
mortality is inversely correlated with age at diagnosis and patients diagnosed with T2D at <30 
years old have a 36% greater mortality risk than those diagnosed at 30-39 years old [4].  
Despite differences in pathophysiology, treatment and prognosis, youth with T2D are 
typically offered clinical care and diabetes education based on programs developed for T1D [6]. 
Pediatric endocrinologists report that compliance is worse in the T2D population and 29% 
reported a more negative attitude toward patients with T2D compared with patients with T1D 
[6].  Poor compliance with medical care and inconsistent visit attendance may contribute to the 
increased morbidity and mortality seen in youth with T2D.  
 In order to improve clinical care of patients with T2D, we must first identify potentially 
modifiable barriers to care which may differ from the T1D population. Potential barriers include 
socioeconomic challenges and cultural or language barriers [6]. In this paper, we utilized the 
Pediatric Diabetes Consortium (PDC) T2D Registry to compare the demographic and clinical 
characteristics of youth with continued follow-up at a pediatric diabetes center versus youth who 
failed to return for follow-up within 18 months.   
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Methods 
Patients 
The PDC began enrollment in February 2012. Data were analyzed from the 496 subjects, 
from 7 U.S. diabetes centers who had been enrolled in the registry for a minimum of 18 months. 
Registry enrollment criteria included age <21 years and a diagnosis of T2D according to the 
American Diabetes Association criteria [7]. All patients had a physician diagnosis of T2D based 
on weight at diagnosis (body mass index >85th percentile for age and gender prior to diabetes 
associated weight loss), metabolic syndrome phenotype and negative diabetes autoantibodies, if 
available. The research protocol was approved by each institution’s IRB and appropriate consent 
and assent were obtained prior to enrollment.  
Data Collection 
Data were collected from the medical record and participant/parent interview at time of 
enrollment and updated yearly. Participant reported race/ethnicity and parent education history 
were obtained. Age, gender, health insurance type, diabetes duration, HbA1c, self-monitoring 
blood glucose tests per day and medication regimen were recorded from patient report and the 
medical record. The distance between patient’s home and the clinic site was approximated using 
latitude and longitude of the center of their respective zip codes. Participants were classified as 
lost to follow-up if they had not had a clinic follow-up visit for >18 months. 
Statistical Analysis 
Enrollment variables (study site, age, gender, race/ethnicity, parent education, diabetes 
duration, hemoglobin A1C, health insurance, blood glucose self-monitoring, distance from site 
and type of diabetes treatment) were chosen a priori by the investigators based on potential 
impact on clinic follow-up or as markers of compliance with the clinical care plan. Continuous 
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data are presented as median (interquartile range: IQR). A univariable logistic regression model 
was used to assess the association of each risk factor with participant status (active or lost to 
follow-up). Then, a multivariable logistic regression model was constructed using stepwise 
selection methods. Only factors with p-value <0.10 during the stepwise selection procedure were 
included in the multivariable model to adjust for possible confounding. Due to multiple 
comparisons, only factors with p-values <0.01 were considered statistically significant. For 
continuous variables, linearity was tested, if non-linear trend was detected, either higher order 
polynomials were added or the variable was discretized. All reported p-values are two-sided. 
Analysis was conducted using SAS version 9.4 (SAS institute, Cary, NC, USA).  
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Results 
The 496 participants had a median (IQR) age of 16.0 years (14.1-17.8) and the majority 
were female (65%). Participants self-identified as Hispanic (54%), African American (30%), 
White (9%) and other (6%). Only 30% of parents had education beyond high school and 62% of 
the participants had Children’s Health Plan or other government health insurance. At enrollment, 
85% were classified as obese (BMI ≥95th percentile for age and gender). The median (IQR) 
HbA1c was 7.3% (6.0-9.4) [56 mmol/mol (42-79)] and participants tested their blood glucose 2 
times per day (1-3). Median (IQR) diabetes duration was 2.1 years (0.8-4.5) at enrollment. After 
a median (IQR) of 1.3 years (0.5-2.3) of follow-up (from enrollment to the last visit date), 55% 
of patients had been lost to follow-up. The median (IQR) follow-up time was 2.3 years (1.9-2.8) 
among those active participants and was 0.7 years (0-1.1) among those lost to follow-up. The 
baseline characteristics of the active participants and the lost to follow-up group are detailed in 
Table 1.  
The univariable and multivariable analyses are presented in Table 2. The only factor that 
met our criteria for significance in the final multivariable model was age. The final model also 
adjusted for race/ethnicity, parent education and estimated distance to study site. Diabetes 
duration, gender and number of blood glucose tests per day were all confounded by age, thus 
were not selected into the final multivariable model.  The odds ratio (99% confidence interval) of 
lost to follow-up was 2.87 (1.34, 6.16) for those 15 - <18 years old vs. the younger participants 
(10 - <13 years old), and was 6.57 (2.67, 16.15) for the adult participants (≥ 18 years old) vs. 
those 10 - <13 years old.  Since older patients may be more likely to leave a pediatric practice 
and seek care from a local adult provider, we also performed a post-hoc analysis excluding 
patients who were ≥ 18 years old at enrollment and found no change in the results. Among 
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patients living more than 50 miles away from the clinic, the odds ratio of lost to follow-up was 
3.11 (1.14, 8.49)  vs. those living within 5 miles of the site. BMI and family status were not 
associated with lost to follow-up rate (data not shown).  
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Discussion 
 In this large, multi-center cohort of youth with T2D, 55% of patients were lost to follow-
up after median of 1.3 years (from enrollment to the last visit date). This high percentage 
highlights the challenges of caring for this population. We found that older adolescents are more 
likely to be lost to follow-up than younger children.  Other socioeconomic factors were not 
significant predictors of clinic follow-up. The rate of lost to follow-up in the PDC registry T2D 
cohort was much higher compared with the T1D cohort, with only 18% lost to follow-up rate 
after a median of 2.9 years (unpublished data). 
 Much of our knowledge about the demographic characteristics of T2D comes from the 
Treatment Options in Type 2 Diabetes in Youth trial (TODAY) and the SEARCH for Diabetes 
study [8, 9]. While T1D accounts for >95% of diabetes diagnoses in white youth, 25% of 
diabetes cases in Hispanic, black and Asian/Pacific Islander patients are T2D [9]. Patients with 
T2D are disproportionately from economically disadvantaged backgrounds as shown in this 
study and the TODAY trial. More than 40% of TODAY study participants reported a household 
income of <$25,000 per year and the majority of parents reported a high school education or less 
[8]. The TODAY study was carefully designed to help minimize barriers to follow-up and 
medication compliance, utilizing a greater number of resources than typical clinical practice. In 
this resource intense setting, more than 90% of randomized patients completed the multi-year 
study (average follow-up 3.8 years) [10]. In contrast, we report more than 50% of patients are 
lost to follow-up in a clinical care setting. The PDC T2D cohort described in this study is 85% 
black or Hispanic and 70% of parents have a high school education or less. In comparison, a 
contemporaneous PDC T1D cohort, drawn from the same pediatric diabetes centers, has almost 
opposite demographics – majority white with relatively high median income and parental 
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education [11]. Despite the vast socioeconomic differences between T1D and T2D patients, 
clinical care for youth with T2D is typically provided in a T1D clinic setting. This care is 
provided by physicians and staff with more experience with T1D than with T2D. Less than a 
quarter of pediatric diabetes clinics report using diabetes education programs designed 
specifically for T2D and most clinics use the same staff to care for both T1D and T2D [6]. T1D 
education programs may fail to recognize the cultural diversity present in T2D clinic 
populations. In order to develop T2D specific diabetes care models, we must address cultural 
differences, language barriers and possible limitations of both reading level and numeracy skills 
in patients with T2D and their parents [12].  
 As clinicians have begun to recognize the unique challenges of T2D, several potential 
barriers to care have been hypothesized. The majority of pediatric diabetes providers have 
identified culture/language as a barrier to successful treatment of T2D [6]. Although we did not 
find that a particular race or ethnicity influenced clinic follow-up, addressing cultural barriers 
may improve T2D care. Other provider concerns have included the unhealthy lifestyle of family 
members and the lack of immediate consequences from uncontrolled T2D [6] for poor follow-up 
seen in T2D youth.  
In this study, the main predictor of loss to follow-up was increasing patient age. Older 
patients may be more likely to receive care from a local adult provider but a post-hoc analysis 
excluding patients ≥ 18 years did not alter our results. Adolescents also report a desire to fit in 
with their peers which interferes with both healthy diet choices and diabetes management [13]. 
However, increasing age has not been associated with loss to follow-up in pediatric weight 
management clinics [14, 15]. Further research is needed to better understand why older 
adolescents are less likely to continue to receive care at pediatric diabetes centers.  
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Financial stress is reported as a barrier to care, impeding access to medications, clinic 
visits and the purchase of healthy foods [13]. We were unable to include patient reported income 
as a variable due to high rates of missing data. Insurance type was used as a surrogate for 
household income but was not associated with clinic loss to follow-up. We were unable to use 
zip code as a surrogate for income as there was poor correlation between our available income 
data and zip code based data from the 2014 5-Year American Community Survey. It does appear 
that distance from the clinic site may influence clinic follow-up. Longer travel distances pose a 
challenge to families without private transportation and longer travel time means more hours of 
missed work. Travel distance has also been associated with unsuccessful transition from 
pediatric to adult sickle cell disease centers [16]. In adults, the majority of studies have shown 
worse health outcomes, including follow-up non-attendance, for patients living further away 
from healthcare facilities [17].  
Novel treatment paradigms utilizing satellite clinics, telemedicine or home health 
services could reduce patient burden and improve access to care. A recent meta-analysis of 55 
randomized controlled trials found that telemedicine provided a larger reduction in HbA1c than 
traditional treatment programs and was particularly effective for T2D vs. T1D [18]. Despite the 
effectiveness in adult populations, none of the 55 studies included pediatric patients with T2D.  
Telemedicine interventions may combine online modules,videoconferencing, or motivational 
text messages or prompts with less frequent clinic or home health visits. Telemedicine has been 
effective in minority, urban and rural populations [19-21].  
 Our study is limited by the lack of data related to why patients stopped seeking care in 
the pediatric diabetes clinic. T2D youth may be receiving medical care from primary care 
providers.  It is possible that primary care providers are more comfortable with the management 
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of T2D and more likely to assume care of adolescents with T2D versus T1D. The main 
advantage of our cohort is that it reflects routine clinical care at 7 pediatric diabetes centers, 
though the efforts of study staff to contact patients may mean that we have underestimated the 
loss to follow-up rate. While clinicians have long suspected poor clinic follow-up in patients 
with T2D, this study is the first to quantify the loss to follow-up rate. We believe that T2D care 
requires a new clinic model that is specifically designed for these adolescent patients and 
addresses the unique socioeconomic, cultural, and language barriers of this population. Next 
steps include evaluating in pediatric clinics the effectiveness of available culturally sensitive 
T2D diabetes education models that have been validated in adult populations [12]. We also 
recommend investigating telemedicine as distance from clinic was an identifiable barrier to care 
for these adolescent patients.  
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Table 1. Participants Characteristics at Enrollment (N=496a) 
 Overall 
N=496 
Lost to Follow-
up 
N=275 
Active 
N=221 
Siteb    
001 77 (16%) 43 (16%) 34 (15%) 
002 109 (22%) 67 (24%) 42 (19%) 
003 47 (9%) 24 (9%) 23 (10%) 
004 90 (18%) 46 (17%) 44 (20%) 
005 25 (5%) 12 (4%) 13 (6%) 
006 67 (14%) 36 (13%) 31 (14%) 
008 81 (16%) 47 (17%) 34 (15%) 
Age (years)    
 <13 75 (15%) 28 (10%) 47 (21%) 
 13−<15 106 (21%) 35 (13%) 71 (32%) 
 15−<18 205 (41%) 128 (47%) 77 (35%) 
 18−<21 110 (22%) 84 (31%) 26 (12%) 
median (25th,75th percentiles) 16.0 (14.1-17.8) 17.0 (15.3-18.5) 14.8 (13.4-16.6) 
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Gender    
Female 320 (65%) 165 (60%) 155 (70%) 
Male 176 (35%) 110 (40%) 66 (30%) 
Race/Ethnicity    
White 44 (9%) 33 (12%) 11 (5%) 
Hispanic or Latino 268 (54%) 150 (55%) 118 (54%) 
Black/African American 149 (30%) 71 (26%) 78 (36%) 
Other/multiracial 31 (6%) 20 (7%) 11 (5%) 
Parent Education    
High School or Less 322 (70%) 176 (69%) 146 (72%) 
Associate 62 (14%) 31 (12%) 31 (15%) 
Bachelor 50 (11%) 32 (13%) 18 (9%) 
Master/Professional Degree 23 (5%) 16 (6%) 7 (3%) 
Health Insurance    
Private 141 (28%) 85 (31%) 56 (25%) 
Children’s Health Plan or Other 
Government 307 (62%) 160 (58%) 147 (67%) 
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Military 3 (<1%) 3 (1%) 0 
None 45 (9%) 27 (10%) 18 (8%) 
Diabetes Duration (years)    
<1 144 (29%) 73 (27%) 71 (32%) 
1-<2 91 (18%) 45 (16%) 46 (21%) 
2-<4 116 (23%) 56 (20%) 60 (27%) 
≥4 145 (29%) 101 (37%) 44 (20%) 
median (25th, 75th percentiles) 2.1 (0.8-4.5) 2.6 (0.9-4.8) 1.8 (0.6-3.5) 
HbA1c % (mmol/mol)    
 <6.0 (<42) 108 (24%) 56 (23%) 52 (25%) 
 6.0−<7.0 (42−<53) 99 (22%) 55 (22%) 44 (21%) 
 7.0−<8.0 (53−<64) 58 (13%) 27 (11%) 31 (15%) 
 8.0−<9.0 (64−<75) 51 (11%) 31 (13%) 20 (10%) 
 ≥9.0 (≥75) 134 (30%) 76 (31%) 58 (28%) 
median (25th, 75th percentiles) 
 
7.3 (6.0-9.4) 
[56 (42-79)] 
7.3 (6.0-9.4) 
[56 (42-79)] 
7.2 (5.9-9.4) 
[55 (41-79)] 
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Self-Monitoring Blood Glucose (# 
tests/day)c 
 
  
0 69 (14%) 44 (16%) 25 (11%) 
1 104 (21%) 62 (23%) 42 (19%) 
2-3 232 (47%) 131 (48%) 101 (46%) 
≥4 91 (18%) 38 (14%) 53 (24%) 
 median (25th, 75th percentiles) 2 (1-3) 2 (1-3) 2 (1-3) 
Diabetes Treatment    
Life-style alone 95 (19%) 55 (20%) 40 (18%) 
Metformin alone 145 (29%) 80 (29%) 65 (29%) 
Insulin alone 106 (21%) 52 (19%) 54 (24%) 
Metformin + Insulin 136 (27%) 77 (28%) 59 (27%) 
Other Med ± Insulin / Metformin 14 (3%) 11 (4%) 3 (1%) 
a. Number of participants with missing or “Unknown” data (lost to follow-up/active): race/ethnicity (1/3), parent 
education (20/19), BMI (26/11), HbA1c (30/16).  
b. Site 007 dropped out of the registry and patient follow up data was unavailable. 
c. Self-reported values.   
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Table 2. Factors at Enrollment Associated with Participants Dropout (N=496) 
 N 
Lost to 
Follow-up 
# (%) 
Univariable 
P-value 
Multivariable 
Odds Ratio 
(99% CI) 
P-
value 
Overall 496 275 (55%)    
Site   0.74  NAa 
001 77 43 (56%)    
002 109 67 (61%)    
003 47 24 (51%)    
004 90 46 (51%)    
005 25 12 (48%)    
006 67 36 (54%)    
008 81 47 (58%)    
Age (years)   <0.001b  <0.001b 
10−<13 75 28 (37%)  Reference  
13−<15 106 35 (33%)  0.74 (0.31, 1.74)  
15−<18 205 128 (62%)  2.87 (1.34, 6.16)  
≥18 110 84 (76%)  6.57 (2.67, 16.15)  
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Gender   0.02  NAa,c 
Female 320 165 (52%)    
Male 176 110 (63%)    
Race/Ethnicityd   0.01  0.06 
White 44 33 (75%)  Reference  
Hispanic or Latino 268 150 (56%)  0.43 (0.15, 1.24)  
Black/African American 149 71 (48%)  0.36 (0.12, 1.11)  
Other/ multiracial 31 20 (65%)  0.66 (0.16, 2.82)  
Parent Educationd   0.13  0.07 
High School or less 322 176 (55%)  Reference  
AA 62 31 (50%)  0.94 (0.42, 2.09)  
BS/BA 50 32 (64%)  1.36 (0.54, 3.45)  
MS/MA/Professional 23 16 (70%)  1.89 (0.51, 6.96)  
Health Insurance   0.26  NAa 
Private 141 85 (60%)    
Children’s Health Plan or 
Other Government 
307 160 (52%)    
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Military 3 3 (100%)    
None 45 27 (60%)    
Diabetes Duration (years)   <0.001b  NAa,c 
<1 144 73 (51%)    
1−<2 91 45 (49%)    
2−<4 116 56 (48%)    
≥4 145 101 (70%)    
HbA1cd % (mmol/mol)   0.94b  NAa 
<6.0 (<42) 108 56 (52%)    
6.0−<7.0 (42−<53) 99 55 (56%)    
7.0−<8.0 (53−<64) 58 27 (47%)    
8.0−<9.0 (64−<75) 51 31 (61%)    
≥9.0 (≥75) 134 76 (57%)    
Self-Monitoring Blood 
Glucose (# tests/day)e 
  0.003b  NAa,c 
0 69 44 (64%)    
1 104 62 (60%)    
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2-3 232 131 (56%)    
≥4 91 38 (42%)    
Diabetes Treatment   0.31  NAa 
Life-style alone 95 55 (58%)    
Metformin alone 145 80 (55%)    
Insulin alone 106 52 (49%)    
Metformin + Insulin 136 77 (57%)    
Other Med ± Insulin / 
Metformin 
14 11 (79%)    
Estimated Distance to Sitef 
(miles) 
  0.10b  0.06b 
<5 106 49 (46%)  Reference  
5-<10 81 40 (49%)  1.19 (0.50, 2.83)  
10-<20 161 93 (58%)  2.27 (1.04, 4.95)  
20-<50 91 55 (60%)  1.78 (0.75, 4.21)  
≥50 57 38 (67%)  3.11 (1.14, 8.49)  
a. Factors with P-value≥0.10 were not included in the multivariate model 
b. Variable was analyzed as continuous. 
c. Main confounding factor is age. 
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d. Missing data: race/ethnicity (4), parent education (39), HbA1c (46). 
e. Self-reported values. 
f. Approximation based on latitude and longitude of the patient’s and site’s zip codes.   
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Table Legends 
Table 1. Participants Characteristics at Enrollment (N=496a) 
a. Number of participants with missing or “Unknown” data (lost to follow-up/active): race/ethnicity (1/3), parent 
education (20/19), BMI (26/11), HbA1c (30/16).  
b. Site 007 dropped out of the registry and patient follow up data was unavailable. 
c. Self-reported values. 
 
Table 2. Factors at Enrollment Associated with Participants Dropout (N=496) 
a. Factors with P-value>0.10 were not included in the multivariate model 
b. Variable was analyzed as continuous. 
c. Main confounding factor is age. 
d. Missing data: race/ethnicity (4), parent education (39), HbA1c (46). 
e. Self-reported values. 
f. Approximation based on latitude and longitude of the patient’s and site’s zip codes.  
 
